Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
Aytu BioPharma (Nasdaq: AYTU) announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Josh Disbrow will engage in a fireside chat on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time. The event is virtual, and interested parties can sign up to view the presentation through a provided link.
Following the event, one-on-one investor meetings will be available upon request. Investors can arrange these meetings by contacting their Maxim representative or Aytu's investor relations group at aytu@lythampartners.com.
Aytu BioPharma is a pharmaceutical company that focuses on commercializing novel therapeutics. This summit participation provides an opportunity for investors to gain insights into the company's operations and future plans.
Aytu BioPharma (Nasdaq: AYTU) ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Il CEO Josh Disbrow parteciperà a una chiacchierata informale il mercoledì 16 ottobre 2024, alle 14:00 ora orientale. L'evento è virtuale e le parti interessate possono registrarsi per visualizzare la presentazione tramite un link fornito.
Dopo l'evento, saranno disponibili incontri individuali con gli investitori su richiesta. Gli investitori possono organizzare questi incontri contattando il proprio rappresentante Maxim o il gruppo di relazioni con gli investitori di Aytu all'indirizzo aytu@lythampartners.com.
Aytu BioPharma è un'azienda farmaceutica che si concentra sulla commercializzazione di terapie innovative. La partecipazione a questo summit offre un'opportunità agli investitori di acquisire informazioni sulle operazioni e sui piani futuri dell'azienda.
Aytu BioPharma (Nasdaq: AYTU) anunció su participación en el 2024 Maxim Healthcare Virtual Summit. El CEO Josh Disbrow participará en una charla informal el miércoles 16 de octubre de 2024, a las 2:00 p.m. hora del Este. El evento es virtual y las partes interesadas pueden registrarse para ver la presentación mediante un enlace proporcionado.
Tras el evento, estarán disponibles reuniones individuales con inversores bajo solicitud. Los inversores pueden organizar estas reuniones contactando a su representante de Maxim o al grupo de relaciones con inversores de Aytu en aytu@lythampartners.com.
Aytu BioPharma es una empresa farmacéutica que se centra en la comercialización de terapeuticas novedosas. La participación en este summit ofrece a los inversores la oportunidad de obtener información sobre las operaciones y los planes futuros de la empresa.
Aytu BioPharma (Nasdaq: AYTU)는 2024 Maxim Healthcare Virtual Summit에 참가한다고 발표했습니다. CEO Josh Disbrow는 2024년 10월 16일 수요일 오후 2시 동부 표준시에 화상 대화에 참여할 예정입니다. 이 행사는 가상으로 진행되며, 관심 있는 분들은 제공된 링크를 통해 발표를 볼 수 있도록 등록할 수 있습니다.
행사 후 요청 시 개별 투자자 회의가 가능합니다. 투자자들은 자신의 Maxim 담당자나 Aytu의 투자자 관계 그룹 aytu@lythampartners.com에 연락하여 회의를 조정할 수 있습니다.
Aytu BioPharma는 혁신적인 치료제를 상용화하는 데 중점을 둔 제약 회사입니다. 이번 서밋 참여는 투자자들이 회사의 운영 및 향후 계획에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
Aytu BioPharma (Nasdaq: AYTU) a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Le PDG Josh Disbrow participera à une discussion informelle le mercredi 16 octobre 2024, à 14h00, heure de l'Est. L'événement est virtuel, et les parties intéressées peuvent s'inscrire pour visionner la présentation via un lien fourni.
À l'issue de l'événement, des réunions individuelles avec des investisseurs seront disponibles sur demande. Les investisseurs peuvent organiser ces réunions en contactant leur représentant de Maxim ou le groupe des relations avec les investisseurs d'Aytu à l'adresse aytu@lythampartners.com.
Aytu BioPharma est une entreprise pharmaceutique qui se concentre sur la commercialisation de thérapies novatrices. La participation à ce sommet offre aux investisseurs une opportunité de mieux comprendre les opérations et les projets futurs de l'entreprise.
Aytu BioPharma (Nasdaq: AYTU) hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit angekündigt. CEO Josh Disbrow wird am Mittwoch, den 16. Oktober 2024, um 14:00 Uhr Eastern Time an einem Gespräch teilnehmen. Die Veranstaltung ist virtuell, und interessierte Parteien können sich über einen bereitgestellten Link anmelden, um die Präsentation anzusehen.
Nach der Veranstaltung stehen eins-zu-eins-Gespräche mit Investoren auf Anfrage zur Verfügung. Investoren können diese Gespräche arrangieren, indem sie ihren Maxim-Vertreter oder die Investor-Relations-Gruppe von Aytu unter aytu@lythampartners.com kontaktieren.
Aytu BioPharma ist ein Pharmaunternehmen, das sich auf die Kommerzialisierung neuer Therapeutika spezialisiert hat. Die Teilnahme an diesem Summit bietet Investoren die Möglichkeit, Einblicke in die Aktivitäten und zukünftigen Pläne des Unternehmens zu gewinnen.
- None.
- None.
DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time.
2024 Maxim Healthcare Virtual Summit Details
Format: Fireside chat
Date: Wednesday, October 16, 2024
Time: 2:00 p.m. Eastern time
Location: Virtual
To sign up to view the presentation, click here.
1x1 investor meetings will be available after the event upon request by contacting your Maxim representative or the Company's investor relations group at aytu@lythampartners.com.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on accesswire.com
FAQ
When is Aytu BioPharma (AYTU) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent Aytu BioPharma (AYTU) at the 2024 Maxim Healthcare Virtual Summit?
What type of presentation will Aytu BioPharma (AYTU) give at the 2024 Maxim Healthcare Virtual Summit?
How can investors view Aytu BioPharma's (AYTU) presentation at the 2024 Maxim Healthcare Virtual Summit?
Are one-on-one meetings available with Aytu BioPharma (AYTU) after the 2024 Maxim Healthcare Virtual Summit?
